Capricor says Deramiocel BLA talks continue with FDA
Capricor Therapeutics says it remains engaged with the FDA on Deramiocel’s BLA after a BIMO inspection produced a Form 483 with one observation that it has addressed.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.